Back to top
more

Aquestive Therapeutics (AQST)

(Delayed Data from NSDQ)

$4.07 USD

4.07
2,934,617

+0.14 (3.56%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $4.02 -0.05 (-1.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

Aquestive Therapeutics (AQST) concluded the recent trading session at $4.14, signifying a +0.24% move from its prior day's close.

Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $4.38, denoting no change from the preceding trading day.

Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals

by Zacks Equity Research

Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.

Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?

by Zacks Equity Research

Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -50% and 12.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Bulls Look Optimistic About Aquestive Therapeutics (AQST): Should You Buy?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Aquestive Therapeutics (AQST). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Aquestive Therapeutics (AQST) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Aquestive Therapeutics (AQST) closed the most recent trading day at $3.67, moving +0.55% from the previous trading session.

Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Investor focus is likely to be on Aquestive Therapeutics' (AQST) updates regarding key pipeline candidate, Anaphylm Sublingual Film, on the fourth-quarter 2023 earnings call.

Aquestive Therapeutics (AQST) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research

In the latest trading session, Aquestive Therapeutics (AQST) closed at $2.65, marking a -1.67% move from the previous day.

Aquestive Therapeutics (AQST) Rises Higher Than Market: Key Facts

by Zacks Equity Research

The latest trading day saw Aquestive Therapeutics (AQST) settling at $2.68, representing a +1.13% change from its previous close.

Why Aquestive Therapeutics (AQST) Outpaced the Stock Market Today

by Zacks Equity Research

Aquestive Therapeutics (AQST) closed at $2.68 in the latest trading session, marking a +1.52% move from the prior day.

Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

Aquestive Therapeutics (AQST) reachead $2.63 at the closing of the latest trading day, reflecting a -1.5% change compared to its last close.

Aquestive Therapeutics (AQST) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

Aquestive Therapeutics (AQST) reachead $2.39 at the closing of the latest trading day, reflecting a +0.84% change compared to its last close.

Aquestive Therapeutics (AQST) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

The latest trading day saw Aquestive Therapeutics (AQST) settling at $2.50, representing a -0.4% change from its previous close.

Aquestive Therapeutics (AQST) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

Aquestive Therapeutics (AQST) closed at $2.63 in the latest trading session, marking a -1.13% move from the prior day.

Here's Why Aquestive Therapeutics (AQST) Fell More Than Broader Market

by Zacks Equity Research

The latest trading day saw Aquestive Therapeutics (AQST) settling at $2.51, representing a -1.95% change from its previous close.

Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel

by Zacks Equity Research

Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum.

Merck (MRK) Begins Pivotal Studies on Four Cancer Candidates

by Zacks Equity Research

Merck (MRK) begins global pivotal studies on bomedemstat, nemtabrutinib, MK-2870 and MK-5684.

Allogene (ALLO) Down 20% on Strategic Changes in Pipeline

by Zacks Equity Research

Allogene (ALLO) decides to deprioritize two pivotal studies for the third-line treatment of certain lymphoma patients and start a new study to focus on the first-line treatment of the indication.

Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study

by Zacks Equity Research

Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response.

Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo

by Zacks Equity Research

Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.

Here's Why You Should Invest in Adverum (ADVM) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.

Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now

by Zacks Equity Research

Here, we discuss some reasons why buying Rigel Pharmaceuticals (RIGL) stock now may turn out to be a prudent move.

Here's Why You Should Invest in Aquestive (AQST) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Aquestive Therapeutics (AQST) stock now may turn out to be a prudent move.

Eli Lilly (LLY) Stock Up 57% in 2023: Will the Uptrend Continue?

by Zacks Equity Research

Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.